Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio
Verified Medicare billing codes support reimbursement access, but coverage remains dependent on eligibility and medical necessity.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Wellspect HealthCare (XRAY) announced traditional Medicare reimbursement access for its Surity urinary management portfolio for eligible beneficiaries with permanent urinary incontinence.
The system and female and male external catheters may be covered when medically necessary and applicable coverage criteria are met. Coding verification supports reimbursement access; individual payers determine coverage and payment, which may vary.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointSurity reimbursement access supports potential traditional Medicare coverage for the system and female and male external catheters.
Negative
- Minor pointCoverage is conditional on beneficiary eligibility, medical necessity and applicable Medicare coverage criteria.
Historical Context
-
U.S. launch of the Surity system completed the portfolio before this reimbursement-access announcement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hcpcs technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Traditional Medicare reimbursement supports broader access to non-invasive management options for eligible beneficiaries living with permanent urinary incontinence
MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S.
The Surity™ portfolio provides non-invasive management solutions for individuals living with urinary incontinence and is designed to make everyday urine management more comfortable, discreet and reliable. Coding verification under Healthcare Common Procedure Coding System (HCPCS) codes A6590 for the Surity™ Female and Male External Catheters and E2001 for the Surity™ Urinary Management System supports reimbursement access for beneficiaries who meet applicable coverage criteria.
“Medicare reimbursement for the Surity™ portfolio represents a significant milestone in our efforts to help individuals living with permanent urinary incontinence benefit from modern solutions that can support their day-to-day needs,” said Chris Schlenk, Group Vice President at Wellspect HealthCare. “For eligible beneficiaries with permanent urinary incontinence, newly established Medicare coding may help reduce barriers to care and expand choice in urinary management. This achievement reflects our ongoing commitment to helping individuals and their caregivers in managing important care needs with solutions designed to support comfort, confidence, and independence.”
For the more than 13 million people living with urinary incontinence in the U.S.,i access to management solutions that address care needs like comfort and rest can have meaningful impact. Traditional Medicare reimbursement access for the Surity™ portfolio helps provide eligible beneficiaries with a new choice, combining gentle suction technology with an intuitive design and features that support quiet operation and odor management, assisting in overnight care and bringing added reassurance to daily routines.
Following the introduction of the Surity™ Female and Male External Catheters earlier in 2026, Wellspect launched the Surity™ Urinary Management System in the United States on August 18, completing the full Surity portfolio. Since its introduction, Surity has become one of the most searched external catheter brands on Google.ii
For additional information* about Surity™, including traditional Medicare coverage requirements and eligibility, visit www.surity.care, where you can also connect with a Wellspect Reimbursement Specialist.
*Whether a product or service is covered by traditional Medicare depends on individual situations and Medicare’s requirements. Coverage, coding, and payment decisions are made by individual payers and may vary. Wellspect HealthCare does not guarantee coverage or reimbursement and is not responsible for payer determinations.
Contact Information Investors:
Wade Moody
Senior Manager, Investor Relations
Investorrelations@dentsplysirona.com
Contact Information Press:
Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
Publicrelations@dentsplysirona.com
About Wellspect HealthCare
Wellspect HealthCare, a subsidiary of Dentsply Sirona (NASDAQ: XRAY) is a leading global provider of innovative medical devices dedicated to improving the quality of life for individuals with bladder and bowel dysfunction.
With approximately 1,200 employees worldwide, Wellspect is committed to making a real difference for people managing continence care needs, empowering them to live each day to the fullest.
Wellspect delivers solutions that support safe bladder and bowel management, while continuously enhancing the experience, clinical performance, and service quality for both healthcare professionals and the people in their care.
As one of the world’s leading manufacturers of intermittent urinary catheters, Wellspect has been at the forefront of innovation since 1983 with its LoFric® brand, which introduced the first hydrophilic-coated catheter.
Wellspect has also pioneered the development of Navina™, an innovative transanal irrigation system designed to support individuals living with chronic bowel disorders.
With advanced Surity™, Wellspect provides reliable urinary incontinence care designed to restore comfort, rest, and confidence for people living with severe urinary incontinence and for their caregivers.
Every day, Wellspect strives to maintain the highest quality standards while minimizing the environmental impact of its products.
Headquartered in Mölndal, Sweden, Wellspect operates in more than 40 countries, offering life-enhancing solutions to people around the world. Dentsply Sirona, the world’s largest diversified manufacturer of professional dental products and technologies, is listed on Nasdaq under the symbol XRAY.
_____________________________
i Leslie SW, Tran LN, Puckett Y. Urinary Incontinence. [Updated 2024 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559095/
ii Google Trends. External Catheter Brands. USA; 2026.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/962344d1-fb85-481b-a8e9-201183fbd79a
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Does traditional Medicare cover Wellspect’s Surity urinary management portfolio?
The Surity system and female and male external catheters may be covered by traditional Medicare for eligible beneficiaries when medically necessary. Applicable coverage criteria must be met, and individual payers make coverage, coding and payment decisions.
Which Medicare billing codes apply to Wellspect’s Surity products?
Coding verification uses A6590 for the Surity Female and Male External Catheters and E2001 for the Surity Urinary Management System. These are Healthcare Common Procedure Coding System codes used to support reimbursement access.
Where can beneficiaries check Surity Medicare eligibility and coverage requirements?
Beneficiaries can visit www.surity.care for traditional Medicare coverage requirements and eligibility information and to connect with a Wellspect Reimbursement Specialist.